WSTNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
WEST PHARMACEUTICAL SERVICES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$383.91−0.11 (-0.03%)
Close on Oct 19, 2026
- Market cap
- $27.37B
- P/E (TTM)
- 49.2
- Dividend yield
- 0.22%
Share price
+$113.31 (+41.87%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
WEST PHARMACEUTICAL SERVICES INC grew revenue 12.4% to $3.33B over the twelve months to Jun 30, 2026. Operating income rose 17.0% to $680.40M, moving the operating margin from 19.6% to 20.5%. Free cash flow was $436.90M, up 27.0% from a year earlier.
Revenue
$3.33B
+12.4% vs. a year earlier
Operating income
$680.40M
+17.0% vs. a year earlier
Free cash flow
$436.90M
+27.0% vs. a year earlier
EPS, diluted
$7.81
+17.1% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $27.37B
- P/E ratio
- 49.2
- Price to sales
- 8.23
- Price to book
- 9.15
- Dividend yield
- 0.22%
- Free cash flow yield
- 1.60%
Fundamentals
- Revenue
- $3.33B
- Net income
- $564.90M
- EPS, diluted
- $7.81
- Free cash flow
- $436.90M
- Book value per share
- $41.94
- Diluted shares
- 71M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$3.33B+12.4% YoY
Gross profit
$1.22B+17.2% YoY
Operating income
$680.40M+17.0% YoY
Net income
$564.90M+15.8% YoY
EPS, diluted
$7.81+17.1% YoY
Free cash flow
$436.90M+27.0% YoY
Reported periodTrailing twelve months